Histamine: A novel approach to cancer immunotherapy

被引:40
作者
Hellstrand, K
Brune, M
Naredi, P
Mellqvist, UH
Hansson, M
Gehlsen, KR
Hermodsson, S
机构
[1] Gothenburg Univ, Dept Virol, S-41346 Gothenburg, Sweden
[2] Gothenburg Univ, Dept Hematol, S-41346 Gothenburg, Sweden
[3] Gothenburg Univ, Dept Surg, S-41346 Gothenburg, Sweden
[4] Maxim Pharmaceut, San Diego, CA USA
关键词
D O I
10.3109/07357900009012178
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The functions of intratumoral lymphocytes in many human malignant tumors are inhibited by reactive oxygen species (ROS), generated by adjacent monocytes/macrophages (MO). In vitro data suggest that immunotherapeutic cytokines such as interleukin-2 (IL-2) or interferon-alpha (IFN-alpha) only weakly activate T cells or natural killer (NK) cells in a reconstituted environment of oxidative stress and that inhibitors of the formation of ROS or scavengers of ROS synergize with IL-2 and IFN-alpha to activate T cells and NK cells. In this review, we focus on the immunoenhancing properties of histamine, a biogenic amine. Histamine inhibits ROS formation in MO via H2-receptors; thereby, histamine protects NK cells from MO-mediated inhibition and synergizes with IL-2 and IFN-alpha to induce killing of NK cell-sensitive human tumor cells in vitro. Histamine also optimizes cytokine-induced activation of several subsets of T cells by affording protection against MO-inflicted oxidative inhibition. The putative clinical benefit of histamine as an adjunct to immunotherapy with IL-2 and/or IFN-alpha is currently evaluated in clinical trials in metastatic malignant melanoma and acute myelogenous leukemia.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 57 条
[51]   EFFECTS OF HISTAMINE, H-1, H-2 AND H-IC RECEPTOR ANTAGONISTS AND ALPHA-FLUOROMETHYLHISTIDINE ON THE GROWTH OF HUMAN COLORECTAL-CANCER IN THE SUBRENAL CAPSULE ASSAY [J].
SUONIO, E ;
TUOMISTO, L ;
ALHAVA, E .
AGENTS AND ACTIONS, 1994, 41 :C118-C120
[52]   LONG-TERM SURVIVAL IN ACUTE MYELOGENOUS LEUKEMIA - A 2ND FOLLOW-UP OF THE 4TH INTERNATIONAL WORKSHOP ON CHROMOSOMES IN LEUKEMIA [J].
SWANSBURY, GJ ;
LAWLER, SD ;
ALIMENA, G ;
ARTHUR, D ;
BERGER, R ;
VANDENBERGHE, H ;
BLOOMFIELD, CD ;
DELACHAPPELLE, A ;
DEWALD, G ;
GARSON, OM ;
HAGEMEIJER, A ;
MITELMAN, F ;
ROWLEY, JD ;
SAKURAI, M .
CANCER GENETICS AND CYTOGENETICS, 1994, 73 (01) :1-7
[53]  
TATSUTA M, 1986, J NATL CANCER I, V76, P277
[54]   Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study [J].
Thalhammer, F ;
Geissler, K ;
Jager, U ;
Kyrle, PA ;
Pabinger, I ;
Mitterbauer, M ;
Gisslinger, H ;
Knobl, P ;
Laczika, K ;
Schneider, B ;
Haas, OA ;
Lechner, K .
ANNALS OF HEMATOLOGY, 1996, 72 (04) :216-222
[55]   Cytokine therapy of malignant melanoma [J].
Villikka, K ;
Pyrhonen, S .
ANNALS OF MEDICINE, 1996, 28 (03) :227-233
[56]   INCREASED LAK AND T-CELL ACTIVATION IN RESPONDING RENAL-CELL CARCINOMA PATIENTS AFTER LOW-DOSE CYCLOPHOSPHAMIDE, IL-2 AND ALPHA-IFN [J].
WERSALL, P ;
MELLSTEDT, H .
MEDICAL ONCOLOGY, 1995, 12 (02) :69-77
[57]  
Whiteside TL, 1998, CURR TOP MICROBIOL, V230, P221